Aptus Capital Advisors LLC Invests $211,000 in Moderna, Inc. (NASDAQ:MRNA)

Aptus Capital Advisors LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,779 shares of the company’s stock, valued at approximately $211,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna during the 4th quarter worth $27,000. Family Firm Inc. acquired a new position in Moderna during the second quarter worth $33,000. Cedar Wealth Management LLC raised its holdings in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. acquired a new stake in shares of Moderna in the first quarter worth about $32,000. Finally, Bank & Trust Co bought a new stake in shares of Moderna during the 2nd quarter worth about $36,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Moderna news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now directly owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here. In the last three months, insiders sold 316,168 shares of company stock valued at $44,094,621. Company insiders own 15.70% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $72.49 on Thursday. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47. The company has a market capitalization of $27.78 billion, a P/E ratio of -4.63 and a beta of 1.67. The stock has a 50 day moving average of $102.13 and a two-hundred day moving average of $112.97. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period last year, the business earned ($3.62) earnings per share. Moderna’s quarterly revenue was down 29.9% compared to the same quarter last year. As a group, equities analysts expect that Moderna, Inc. will post -9.52 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MRNA shares. Barclays cut their price objective on Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a research note on Friday, August 2nd. The Goldman Sachs Group reduced their price objective on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price on the stock in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada downgraded Moderna from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $125.00 to $90.00 in a research report on Monday, August 5th. Ten investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $123.79.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.